Articles From: Tetraphase Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference to Texas Capital Bank Ranks in the Top 20 on the 2015 Forbes Best Banks in America List


Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , a clinical-stage biopharmaceutical company whose lead product candidate, eravacycline, is being developed as a broad-spectrum intravenous and oral antibiotic designed to be effective against multidrug-resistant bacteria, today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer , will present at the Oppenheimer 25 th Annual Healthcare Conference on Thursday, December 11 at 1:00 p.m. Eastern Time.
Sign-up for Tetraphase Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) approved QNASL ® (beclomethasone dipropionate) 40 mcg for the treatment of nasal symptoms associated with allergic rhinitis (AR) in children 4-11 years of age.
Sign-up for Teva Announces FDA Approval of QNASL® (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces Launch of First Generic Celebrex® Capsules in the United States investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Announces Launch of Generic Exforge HCT® Tablets in the United States investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Launches Generic Diovan® in the United States investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the commercial availability of a liquid formulation of TREANDA ® (bendamustine HCI) Injection.
Sign-up for Teva Launches Liquid Formulation of TREANDA® (bendamustine HCI) Injection in U.S. investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that four company-sponsored abstracts evaluating the safety and efficacy of albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated, dry-powder, short-acting beta-agonist (SABA), will be presented at the 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Atlanta, Georgia on November 6-10, 2014.
Sign-up for Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced positive findings from a Phase III clinical study that examined the safety and efficacy of QNASL ® (beclomethasone dipropionate) Nasal Aerosol 80 μg/day in children 4-11 years of age with perennial – or “year round” – allergic rhinitis (PAR). QNASL is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhinitis (SAR) in patients 12 years of age and older.
Sign-up for Teva Presents Positive Safety and Efficacy Data for QNASL® (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Provides 2015 Business Outlook investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that it has received a positive outcome in the decentralized procedure for its new, three-times-a-week COPAXONE ® (glatiramer acetate) 40 mg/ml formulation for the treatment of adults with relapsing forms of multiple sclerosis (RMS). The outcome follows a Positive Assessment Report from the United Kingdom, the Reference Member State’s Medicines and Healthcare Products Regulatory Agency (MHRA), and all Concerned Member States (CMS) in Europe who were involved in the procedure.
Sign-up for Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS) investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva Reports Third Quarter 2014 Results investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva to Host 2015 Business Outlook Conference Call and Webcast on December 11, 2014 investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for Teva to Report Fourth Quarter 2014 Financial Results on February 5, 2015 investment picks
http://media.marketwire.com/attachments/201305/153616_60427_ADPlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163976&ProfileId=051205&sourceType=1 ROSELAND, NJ --
Sign-up for Texas Added 29,700 Private Sector Jobs in November, According to ADP Regional Employment Report(R) investment picks
http://media.marketwire.com/attachments/201305/153616_60427_ADPlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1158094&ProfileId=051205&sourceType=1 ROSELAND, NJ --
Sign-up for Texas Added 30,450 Private Sector Jobs in October, According to ADP Regional Employment Report(R) investment picks
http://media.marketwire.com/attachments/201305/153616_60427_ADPlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1168914&ProfileId=051205&sourceType=1 ROSELAND, NJ --
Sign-up for Texas Added 31,100 Private Sector Jobs in December, According to ADP Regional Employment Report(R) investment picks
2014/12/3
By Philip van Doorn, MarketWatch The Lone Star state, home to the energy industry, suffers collateral damage Oil companies aren't the only ones taking a pounding from the tumble in crude prices.
Sign-up for Texas bank stocks dinged by drop in oil prices investment picks
2014/12/3
For comparison, the FDIC said in its quarterly banking profile that the aggregate third-quarter return on assets for all U.S. banks was 1.02% and the return on average equity was 9.04%. The aggregate ratio of noncurrent loans to total loans was 2.11%. To test reserve adequacy, it is best to compare loan charge-off rates to reserve coverage.
Sign-up for Texas bank stocks dinged by drop in oil prices -2- investment picks
DALLAS, Nov.
Sign-up for Texas Capital Bancshares, Inc. Announces Common Stock Offering investment picks
DALLAS, Jan.
Sign-up for Texas Capital Bancshares, Inc. Announces Q4 2014 Earnings Call investment picks
DALLAS, Nov.
Sign-up for Texas Capital Bancshares, Inc. Prices Common Stock Offering investment picks
2014/12/1
DALLAS, Dec.
Sign-up for Texas Capital Bank Ranks 11th in Dallas Morning News Top 100 Places to Work investment picks
2015/1/9
DALLAS, Jan.
Sign-up for Texas Capital Bank Ranks in the Top 20 on the 2015 Forbes Best Banks in America List investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Tetraphase Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference to Texas Capital Bank Ranks in the Top 20 on the 2015 Forbes Best Banks in America List
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent